Literature DB >> 1617365

Clinical observation of assessment using the Composite International Diagnostic Interview (CIDI). An analysis of the CIDI Field Trials--Wave II at the St Louis site.

A Janca1, L N Robins, L B Cottler, T S Early.   

Abstract

Two clinicians scored the ICD-10 Research Criteria Checklist either while observing or after administering CIDI interviews to a sample of 20 subjects. Overall diagnostic concordance between clinical and CIDI assessments was found to be good (overall kappa = 0.77). Assessment of the specific diagnoses could be done only for the three most commonly represented in the studied sample: anxiety/phobic disorders (kappa = 0.73), depressive disorders (kappa = 0.78), and psychoactive substance use disorders (kappa = 0.83). While the lack of independence of the two assessments and the small, non-randomly selected sample might have exaggerated the concordance, this study shows that the CIDI provides all the data needed to score diagnoses in the ICD-10 nomenclature, as indicated by the small number of questions clinicians needed to ask following completion of the CIDI.

Entities:  

Mesh:

Year:  1992        PMID: 1617365     DOI: 10.1192/bjp.160.6.815

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  28 in total

1.  Gender differences in the prevalence of depression among Canadian adolescents.

Authors:  J Cairney
Journal:  Can J Public Health       Date:  1998 May-Jun

Review 2.  Psychiatric assessment instruments developed by the World Health Organization.

Authors:  N Sartorius; A Janca
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1996-03       Impact factor: 4.328

3.  Development and feasibility of the computerized Turkish edition of the Composite International Diagnostic Interview [DIA-X/CIDI version 2.8(TR)].

Authors:  Demet Dingoyan; Mike Mösko; Yadigar Imamoğlu; Alessa von Wolff; Jens Strehle; Hans-Ulrich Wittchen; Holger Schulz; Uwe Koch-Gromus; Andreas Heinz; Ulrike Kluge
Journal:  Int J Methods Psychiatr Res       Date:  2016-10-21       Impact factor: 4.035

4.  Longitudinal predictors of cannabis use and dependence in offspring from families at ultra high risk for alcohol dependence and in control families.

Authors:  Shirley Y Hill; Bobby L Jones; Stuart R Steinhauer; Nicholas Zezza; Scott Stiffler
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2016-01-12       Impact factor: 3.568

5.  Maladaptive decision making and substance use outcomes in high-risk individuals: preliminary evidence for the role of 5-HTTLPR variation.

Authors:  Jessica W O'Brien; Sarah D Lichenstein; Shirley Y Hill
Journal:  J Stud Alcohol Drugs       Date:  2014-07       Impact factor: 2.582

6.  ACN9 and alcohol dependence: family-based association analysis in multiplex alcohol dependence families.

Authors:  Shirley Y Hill; Bobby L Jones; Nicholas Zezza; Scott Stiffler
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2015-04       Impact factor: 3.568

7.  Patterns of sexual risk behaviors and psychiatric disorders in a community sample of young adults.

Authors:  Jonathan G Tubman; Andrés G Gil; Eric F Wagner; Henry Artigues
Journal:  J Behav Med       Date:  2003-10

8.  Disruption of orbitofrontal cortex laterality in offspring from multiplex alcohol dependence families.

Authors:  Shirley Y Hill; Shuhui Wang; Bryan Kostelnik; Howard Carter; Brian Holmes; Michael McDermott; Nicholas Zezza; Scott Stiffler; Matcheri S Keshavan
Journal:  Biol Psychiatry       Date:  2008-11-04       Impact factor: 13.382

9.  Cerebellar volume in offspring from multiplex alcohol dependence families.

Authors:  Shirley Y Hill; Srirangam Muddasani; Konasale Prasad; Jeffrey Nutche; Stuart R Steinhauer; Joelle Scanlon; Michael McDermott; Matcheri Keshavan
Journal:  Biol Psychiatry       Date:  2006-03-14       Impact factor: 13.382

10.  Suicidal ideation and aggression in childhood, genetic variation and young adult depression.

Authors:  Shirley Y Hill; Bobby L Jones; Gretchen L Haas
Journal:  J Affect Disord       Date:  2020-07-24       Impact factor: 4.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.